3 Results for "

p-cRaf

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "p-cRaf" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-122914
CAS No.: 900897-56-5
Purity:  99.65%
Target:  

Ras

Research Areas:  

Cancer

KRAS inhibitor-3 is an inhibitor of KRAS inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (KD: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf .
loading...
    loading...
Cat. No.: HY-146223
Purity:  99.52%
Target:  

Ras p38 MAPK PI3K Apoptosis

Research Areas:  

Cancer

AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-146223A
Purity:  98.00%
Target:  

Ras PI3K p38 MAPK Apoptosis

Research Areas:  

Cancer

(3R,10R,14aS)-AZD4625 is the isomer of AZD4625 (HY-146223), and can be used as an experimental control. AZD4625 is an orally active, selective irreversible, covalent allosteric GTPase KRASG12C inhibitor with an IC50 of 3 nM. AZD4625 can inhibit the MAPK pathway (with decreased pCRAF, pMEK, and pERK) and the PI3K pathway (with decreased pAKT and pS6), and induce cell apoptosis. AZD4625 has no binding and inhibition of wild-type RAS or isoforms carrying non-KRASG12C mutations. AZD4625 can be used for the study of KRASG12C mutant non-small cell lung cancer .
loading...
    loading...